Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Acquisition of Freeline by Syncona Becomes Effective Acquisition of Freeline by Syncona Becomes Effective

Freeline Shareholders Approve Acquisition by Syncona Freeline Shareholders Approve Acquisition by Syncona

Syncona to Acquire Freeline Therapeutics Syncona to Acquire Freeline Therapeutics

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Con